Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway
NCT: NCT07024550 · ACTIVE_NOT_RECRUITING
Brief Summary
The goal of this clinical trial is to thoroughly explore and ascertain the mechanism of action of the therapy with the EXOMIND (BTL-699-2) device in the treatment of food cravings (serving as an important precipitant to binge eating episodes), among binge eaters and to confirm its efficacy and safety, in adult binge-eating patients with food cravings. The main question it aims to answer is: To ascertain the mechanism of action of the treatment with the EXOMIND (BTL-699-2) device equipped with a BTL-699-AP-M-2 applicator in reducing food cravings, for the active group only. Participants will complete six treatments and one follow-up visit.
Frequently Asked Questions
What is Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway?
Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway is a clinical trial registered under NCT07024550. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT07024550?
The current status of NCT07024550 (Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway) is: ACTIVE_NOT_RECRUITING.
When did Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway start?
Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway started on 2025-07-22.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.